Cargando…
Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease
PURPOSE: Platelet rich plasma (PRP) is an autologous preparation that concentrates platelets in a small volume of plasma. The purpose of this study was to determine if PRP eye drops improved the symptoms and signs of ocular surface disease. PATIENTS AND METHODS: A retrospective case series was condu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762402/ https://www.ncbi.nlm.nih.gov/pubmed/36544899 http://dx.doi.org/10.2147/OPTH.S391536 |
_version_ | 1784852855350362112 |
---|---|
author | Nadelmann, Jennifer B Bunya, Vatinee Y Ying, Gui-Shuang Hua, Peiying Massaro-Giordano, Mina |
author_facet | Nadelmann, Jennifer B Bunya, Vatinee Y Ying, Gui-Shuang Hua, Peiying Massaro-Giordano, Mina |
author_sort | Nadelmann, Jennifer B |
collection | PubMed |
description | PURPOSE: Platelet rich plasma (PRP) is an autologous preparation that concentrates platelets in a small volume of plasma. The purpose of this study was to determine if PRP eye drops improved the symptoms and signs of ocular surface disease. PATIENTS AND METHODS: A retrospective case series was conducted of patients who were prescribed PRP eye drops. Subjects were excluded if they did not have follow-up, underwent intraocular surgery prior to follow-up, received nerve growth factor treatments, or did not have a baseline examination with photography. Symptoms were assessed using the Ocular Surface Disease Index (OSDI). Patients also underwent a slit lamp exam, ocular surface staining with fluorescein and lissamine green, and Schirmer testing. RESULTS: The charts of 47 patients treated with PRP drops for ocular surface disease were reviewed. Sixty-four eyes of 32 patients were included in the study who had photographs of lissamine green staining taken at baseline and at follow-up. Thirteen patients (28%) had ocular graft-versus-host disease, 16 patients (34%) had Sjögren’s syndrome, and 4 patients (8.5%) had rheumatoid arthritis. There was a statistically significant decrease in OSDI score from baseline to follow-up (39.5 vs 30.8 points, p = 0.02). Among the 64 eyes included, 9 (14%) had an improvement in conjunctival lissamine green staining, while 6 (9%) had an increase in staining at follow-up. Among the 20 eyes with Schirmer testing, there was a borderline significant increase in score from baseline to follow-up (5.9 vs 9.7, p = 0.06). Among the 44 eyes that had corneal fluorescein staining (CFS) reported, 8 (18.2%) had decreased staining and 2 (4.5%) had increased staining at follow-up. CONCLUSION: Treatment with PRP drops was associated with a significant improvement in symptoms in patients with ocular surface disease. Future larger prospective studies are needed to further evaluate the efficacy of PRP drops for treating ocular surface disease. |
format | Online Article Text |
id | pubmed-9762402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97624022022-12-20 Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease Nadelmann, Jennifer B Bunya, Vatinee Y Ying, Gui-Shuang Hua, Peiying Massaro-Giordano, Mina Clin Ophthalmol Original Research PURPOSE: Platelet rich plasma (PRP) is an autologous preparation that concentrates platelets in a small volume of plasma. The purpose of this study was to determine if PRP eye drops improved the symptoms and signs of ocular surface disease. PATIENTS AND METHODS: A retrospective case series was conducted of patients who were prescribed PRP eye drops. Subjects were excluded if they did not have follow-up, underwent intraocular surgery prior to follow-up, received nerve growth factor treatments, or did not have a baseline examination with photography. Symptoms were assessed using the Ocular Surface Disease Index (OSDI). Patients also underwent a slit lamp exam, ocular surface staining with fluorescein and lissamine green, and Schirmer testing. RESULTS: The charts of 47 patients treated with PRP drops for ocular surface disease were reviewed. Sixty-four eyes of 32 patients were included in the study who had photographs of lissamine green staining taken at baseline and at follow-up. Thirteen patients (28%) had ocular graft-versus-host disease, 16 patients (34%) had Sjögren’s syndrome, and 4 patients (8.5%) had rheumatoid arthritis. There was a statistically significant decrease in OSDI score from baseline to follow-up (39.5 vs 30.8 points, p = 0.02). Among the 64 eyes included, 9 (14%) had an improvement in conjunctival lissamine green staining, while 6 (9%) had an increase in staining at follow-up. Among the 20 eyes with Schirmer testing, there was a borderline significant increase in score from baseline to follow-up (5.9 vs 9.7, p = 0.06). Among the 44 eyes that had corneal fluorescein staining (CFS) reported, 8 (18.2%) had decreased staining and 2 (4.5%) had increased staining at follow-up. CONCLUSION: Treatment with PRP drops was associated with a significant improvement in symptoms in patients with ocular surface disease. Future larger prospective studies are needed to further evaluate the efficacy of PRP drops for treating ocular surface disease. Dove 2022-12-15 /pmc/articles/PMC9762402/ /pubmed/36544899 http://dx.doi.org/10.2147/OPTH.S391536 Text en © 2022 Nadelmann et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Nadelmann, Jennifer B Bunya, Vatinee Y Ying, Gui-Shuang Hua, Peiying Massaro-Giordano, Mina Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title | Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title_full | Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title_fullStr | Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title_full_unstemmed | Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title_short | Effect of Autologous Platelet-Rich Plasma Drops in the Treatment of Ocular Surface Disease |
title_sort | effect of autologous platelet-rich plasma drops in the treatment of ocular surface disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762402/ https://www.ncbi.nlm.nih.gov/pubmed/36544899 http://dx.doi.org/10.2147/OPTH.S391536 |
work_keys_str_mv | AT nadelmannjenniferb effectofautologousplateletrichplasmadropsinthetreatmentofocularsurfacedisease AT bunyavatineey effectofautologousplateletrichplasmadropsinthetreatmentofocularsurfacedisease AT yingguishuang effectofautologousplateletrichplasmadropsinthetreatmentofocularsurfacedisease AT huapeiying effectofautologousplateletrichplasmadropsinthetreatmentofocularsurfacedisease AT massarogiordanomina effectofautologousplateletrichplasmadropsinthetreatmentofocularsurfacedisease |